Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016

Weekending:- 14-06-2019

Legal Publication Date:- 27-06-2019

Journal Code (190627)

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

10-06-2019		
401/2019	SYNGENTA CROP PROTECTIOIN AG, Switzerland (Priority 06-06-2018 IN)	"Pesticidally active heterocyclic derivatives with sulfur containing substituents"
402/2019	Sunita Hydrocolloids Inc., USA (Priority 08-06-2018 US)	"FRICTION REDUCERS, FRACTURING FLUID COMPOSITIONS AND USES THEREOF"
403/2019	Alibaba Group Holdings Limited, Cayman Islands (Priority 08-06-2018 CN)	"FINANCING LOAN METHODS AND APPARATUS"
404/2019	Top Cap Holding GmbH, Austria (Priority 19-06-2018 EP)	"Metallic can end"
405/2019	XEROS LIMITED, United Kingdom (Priority 12-06-2018 UK)	"METHOD FOR THE CONTDITIONING OF TEXTILES AND CONDITIONED TEXTILES PRODUCED THEREBY"
11-06-2019		
406/2019	CHIESI FARMACUEITICI S.p.A., Italy (Priority 13-06-2018 EP)	"AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS"
407/2019	PFIZER INC. USA	"GLP-1 RECEPTOR AGONIST AND USES THEREOF"

	(Priority 13-06-2018 US)	
12-06-2019		
408/2019	ARYSTA LIFESCINECE INC., USA (Priority 13-06-2018 US)	"PROCESS FOR PREPARATION OF THIOCYCLAM BASE AND SALT"
409/2019	Alibaba Group Holding Limited Cayman Islands (Priority 13-06-2018 CN)	"METHODS AND APPARATUS FOR PRE-REDEEMING AVAILABLE RESOUCE QUOTA BASED ON BLOCKCHAIN"
410/2019	GONZALEZ SANCHEZ, JOSE FRANCISCO Spain (Priority 12-06-2018 Spain)	"COLLAPSIBLE CAP FOR CONTAINERS"
411/2019	ELI LILLY AND COMPANY USA (Priority 22-06-2018 US)	"GIP/GLP1 AGONIST COMPOSITIONS"
412/2019	Prof. Dr. Allah Bakhsh Dr. Muhammad Adnan Shahid Mr. Babar Ijaz Engr. Usman Iqbal University of Agriculture Faisalabad - Pakistan	"Android Soil Moisture Meter"
413/2019	Dr. Anjum Munir Mr. Mian Ali Mehmood Dr. Abdul Ghafoor Dr. Waseem Amjad Engr. Talha Ashraf University of Agriculture Faisalabad - Pakistan	"SCOPE-UP: Solar Cold Storage for Perishables with Engery-Efficient Ultimate Cooling Pads"

13-06-2019		
414/2019	JANSSEN PHARMACEUTICA NV, Belgium (Priority 15-06-2018 US)	"SMALL MOLECULE INHIBITORS OF THE JAK FAMILY OF KINASES"
415/2019	Alibaba Group Holding Limited Cayman Islands (Priority 13-06-2018 CN)	"METHODS AND APPARATUS FOR REDEEMING AVAILABLE RESOUCE QUOTA BASED ON BLOCKCHAIN"
416/2019	Alibaba Group Holding Limited Cayman Islands (Priority 13-06-2018 CN)	"METHODS AND APPARATUS FOR REDEEMING AVAILABLE RESOUCE QUOTA BASED ON BLOCKCHAIN BY USING SET"
417/2019	Alpinestars Reasearch Srl Italy (Priority 15-06-2018 IT)	"METHOD FOR JOINING TOGETHER TWO PROTECTIVE MATERAILS AND PROTYECTIVE GARMENT COMPRISING AN ARTICLE MADE USING THIS METHOD"
418/2019	Top Cap Holding GmbH, Austria (Priority 19-06-2018 EP)	"Metallic can end"
419/2019	SICPA HOLDING SA Switzerland (Priority 30-07-2018 EU)	"A MULTI-CHIP MODULE (MCM) ASSEMBLY AND A PRINTING BAR"
420/2019	SICPA HOLDING SA Switzerland (Priority 30-07-2018 EU)	"A MULTI-CHIP MODULE (MCM) ASSEMBLY"
421/2019	SICPA HOLDING SA Switzerland (Priority 30-07-2018 EU)	"A MODULE SERVICE STATION AND METHOD OF SERVICING AN INKJET PRINTHEAD OF AN INKJET PRINTING SYSTEM"

422/2019	MUHAMMAD IQBAL NAVEED IQBAL Rahim Yar Khan - Pakistan	"DECORATIVE AND ADVERTISING KINETIC MONUM+ENTS"
423/2019	SICPA HOLDING SA Switzerland (Priority 30-07-2018 EU)	"INK DELIVERY SYSTEM FOR A PRINTING MODULE AND METHOD FOR DELIVERING INK"
424/2019	Dr. Sajjad Manzoor Shahid Akram Ali Mahmood Muhammad Tahir Mujtabah Ali Bin Yasin Mirpur – AJK – Pakistan	"A device for motion assistance of the visually impaired person"
14-06-2019		
425/2019	Aabshar Solution (Pvt) Ltd Lahore - Pakistan	"AABSHAR WATER OPTIMIZER"
426/2019	Levi Strasuss & Co., US (Priority 14-06-2018 US)	"FABRIC WITH ENHANCED RESPONSE CHARACTERISTICS FOR LASER FINISHING"
427/2019	AstraZeneca AB Sweden Cancer Research Technology Limited GB (Priority 15-06-2018 US)	"Purinone Compounds and Their Use in Treating Cancer"
428/2019	UCB Pharma GmbH Germany (Priority 19-06-2018 EP)	"PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES"
429/2019	Seren Technologies Limited	"COUNTERCURRENT RARE EARTH

	United Kingdom (Priority 15-06-2018 UK)	SEPARATION PROCESS"
430/2019	Seren Technologies Limited United Kingdom (Priority 15-06-2018 UK)	"ENHANCED SEPARATION OF RARE EARTH METALS"
431/2019	Seren Technologies Limited United Kingdom (Priority 15-06-2018 UK)	"RARE EARTH METAL OXIDE PREPARATION"
432/2019	Seren Technologies Limited United Kingdom (Priority 15-06-2018 UK)	"IONIC LIQUID PREPARATION"

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be as certained on application to the office.

476/2001	Novartis AG Switzerland	"A HYDROXY-1-AZO-BENZENE COMPOUND AS THROMBOPOIETIN MIMETIC" C07D213/20, C07D257/04 & A61K31/41. **143154** Disclosed is a compound selected from the group consisting of: {N' [1 -(3 ,4-Dimethylphenyl)-3 -methyl-5-oxo- 1 ,5-dihydropyrazol-4-ylidene]hydrazino } -2'-hydroxybiphenyl-3-carboxylic acid; { N' -[1 -(3 ,4-Dimethylphenyl)-3 -methyl-5-oxo- 1 ,5-dihydropyrazol-4-ylidene]hydrazino } -3'-hydroxybiphenyl-4-carboxylic acid; 3' {N '-[1 -(3 ,4-dimethylphenyl)-3 -methyl-5-oxo- 1 ,5-dihydropyrazol-4-ylidene]hydrazino } -2hydroxy-3'-(tetrazol-5-yl)biphenyl; 3'- {N' -[1 -(4-tert-butylphenyl)-3-methyl-5-oxo- 1,5 -dihydropyrazol-4-ylidene]hydrazino } -2'hydroxybiphenyl-3-carboxylic acid; 3-Aza-3 '- {N'-[1 -(4-tert-butylphenyl)-3-methyl-5-oxo- 1 ,5-dihydropyrazol-4-ylidene] hydrazino } - 2' -hydroxybiphenyl-5-

		carboxylic acid; 3- {N' -[1 -(3 -4-dimethylphenyl)-3 -methyl-5-oxo- 1 ,5-dihydropyrazol-4-ylidene]hydrazino } -2hydroxy-3'-(tetrazol-5-yl)biphenyl; 3- {N' -(3 ,4-dimethylphenyl)-3-methyl-5-oxo- 1 ,5-dihydropyrazol-4-ylidene]hydrazino } -2hydroxy-3'-(tetrazol-5-yl)biphenyl, and pharmaceutical composition comprising said compound for treating thrombocytopenia, in a mammal, including a human.
698/2006	Novartis AG Switzerland	"A PHARMACEUTICALLY ACCEPTABLE SALT OF A HYDROXY-1-AZO--BENZENE COMPOUND" C 07D213/20, C07D257/04 & A61K 31/41. **143155** Invented is a pharmaceutically acceptable salt, hydrate, solvate and ester of a compound represented by the following Formula (I):  (I) wherein R, R^1, R^2, R^3, AR and m are as defined herein, as a non-peptide TPO mimetics. Also invented is a novel process for the preparation of the presently invented compound. Also invented is a pharmaceutical composition comprising the said compound for treating thrombocytopenia, in

		a mammal, including a human.
1328/2007	PLEXXIKON, INC., U.S.A.	"Pyrrolo[2,3-b]pyridine Compound for Modulating C-fms and/or C-kit Activity" C07D471/04 & A61K31/437. **143156** Compound active on the receptor protein tyrosine kinases c-kit and/or c-fms is provided herewith. Also provided herewith is composition useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions.
1042/2010	H. LUNDBECK A/S Denmark.	"Heteroaromatic aryl triazole derivative as PDE10A enzyme inhibitor" C07D 471/04, A61K 31/4196, A61K31/437, A61P25/28 & A61P25/18. **143157** This invention is directed to compound, which are PDE10A enzyme inhibitor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compound of formula I. The present invention further provides a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

1043/2010	H. LUNDBECK A/S Denmark.	"Heteroaromatic compound as PDE10A enzyme inhibitor" C07D487/04, C07D471/04,A61K 31/519 & A61P 25/00 **143158** This invention is directed to compound, which are PDE10A enzyme inhibitor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
59/2012	Shahid Rahman S/O Khan Bahdur Abdur Rahman Khan Lahore - Pakistan	"Method of manufacturing Changeable Footwear" A43B3/24. **143159** The invention relates to the field of "Changeable footwear", and particularly to the method of manufacturing of changeable footwear for assembly and replacement of uppers/ outsoles by the user to change the appearance/color of their footwear as desired. The method comprises basically of: • Making the changeable upper elastic/flexible.

		• Making the changeable upper separably attachable to outsole • Making the changeable outsole separably attachable to upper. • Method of assembly /replacement of the said uppers/outsoles. -The said method comprises of a stand-alone out-sole compatible along with the stand-alone upper comprising design/style and construction elements, of male/female/children footwear made of appropriate material/s are "made" separably attachable embodying, but not limited to, receptors/hooks or other similar devices in-built/attached, comprising of appropriate length/s. depth & number, along the periphery of the outsole, with matching locations/size of eyelets/ slits/slots, flexible elastic element, and the in-sole embodying the said upper. The method of manufacture enables replacement/assembly of uppers/out-soles by the end user through pinch and release process.

		FIGURE - C  FIG.- C1  FIG.- C2  FIG.- C3

551/2013	Stora Enso Oyj Finland	"Method and cellulosic pulp for the production of highly refined or micro- fibrillated cellulose" C08L1/02, D21B1/34, D21C 9/00 & D21C 9/18. **143160** The invention concerns a method for the production of highly refined or microfibrillated cellulose (MFC), comprising the steps of treating cellulosic fibres to remove at least a major part of the primary wall of the fibres, drying the treated fibres, rewetting the treated fibres, and disintegrating the wetted fibres by mechanical means to obtain the final product. The invention further concerns dried cellulosic pulp as an intermediate product of the method, having an average fibre length of at least 0.4 mm, while less than 50% of the primary wall material of natural untreated fibres is left in the intermediate product. Instead of transporting large amounts of dilute MFC dispersion the invention enables transport of the dry intermediate product to the MFC end user, who would complete the process by turning the intermediate product to final MFC by use of standard disintegrating devices.
706/2013	UPL Limited, India.	"Fungicidal composition of Mancozeb and Chlorotholanil" A01N 25/12, A01N47/34 & A01N 37/34. **143161** The present invention provides a fungicidal composition comprising a fungicidally effective amount of mancozeb and a fungicidally effective amount of chlorothalonil in a ratio of about 5: 1, wherein the total weight of mancozeb and chlorothalonil together is about 75% by weight of the composition. The composition is useful in combating fungal infection and exhibit remarkable fungicidal activities for pathogenic fungi such as foliar late blight, Alternaria leaf spot. The composition also increases the

		vigor/yield of the plant.
896/2013	PFIZER INC. U.S.A.	"-3,4-DIHYDROISOQUINOLIN-1(2H)-ONE COMPOUND" C07D 401/06, C07D 401/14, C07D 403/14, C07D 471/04, C07D413/06, C07D413/14 & C07D 407/14. **143162** The present invention relates to compound of formula (II-A):  (II-A), wherein; R^1 is C_1-C_4 alkyl or halo; R^2 is 5-6 membered heteroaryl optionally substituted by 1 to 3 R^{32}; R^3 is H; R^4 is H or halo; m is 0 and R^5 is absent; each R^{32} is independently -Cl, -F, -OH, -CH_3, -CH_2CH_3, -CF_3, -CH_2OH, -CH_2OCH_3, -OCH_3, -OC_2H_5, -OCF_3, -CN, -$C(O)NH_2$, -$C(O)NHCH_3$, -$C(O)N(CH_3)_2$, -$NHC(O)CH_3$, -NH_2, - $NHCH_3$, -$N(CH_3)_2$, cyclopropyl, 4-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, where said 4-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl are optionally substituted by 1 to 3 halo, C_1-C_4 alkyl or C_1-C_4 alkoxy, which are independently selected; X and Z are independently C_1-C_4 alkyl; and

		Y is H. The present invention further provides a pharmaceutical composition comprising above said compound and a pharmaceutically acceptable carrier or excipient which is useful for treatment of abnormal cell growth, including cancer.
186/2014	Galapagos NV Belgium.	"NOVEL AUTOTAXIN INHIBITOR" C07D471/04, A61K31/437, A61P 35/00, A61P 37/00, A61P9/00, A61P25/08, A61P11/00 & A61P 29/00. **143163** The present invention relates to compound inhibiting autotaxin (NPP2 or ENPP2) according to Formula I:  I wherein R^{1a}, R^{1b}, R^2, R^4, R^5, R^{6a}, R^{6b}, R^7, R^8, W, X, Cy, and the subscript a are as defined herein, method for its production, pharmaceutical composition comprising the same, and using the same for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases.
753/2014	SYNGENTA LIMITED, Great Britain and	"Pyridinylimidazolones as herbicides" A01N43/50 & C07D401/04.

	Syngenta Participations AG Switzerland	**143164** The invention relates to herbicidal compound of formula (I)  (I) wherein X is selected from O and S; R^a is selected from hydrogen and halogen; R^b is selected from hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxy, C_2-C_4 alkenyloxy, C_2-C_4 alkynyloxy, C_1-C_4 alkoxy C_1-C_4 alkyl ,C_1-C_4 alkoxy-C_1-C_4 alkoxy, C_1-C_4 alkoxy C_1-C_4 alkoxy C_1-C_4 alkyl, C_1-C_4 haloalkoxy, C_1-C_4 alkylthio, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, a group R^5R^6N-, a group $R^5C(O)N(R^6)$-, a group $R^5S(O_2)N(R^6)$-, a group $R^5R^6NSO_2$-, a group $R^5R^6NC(O)$-, aryl optionally substituted by from 1 to 3 groups independently selected from halogen, nitro, cyano, $R^5C(O)N(R^6)$-, $R^5R^6NC(O)$-, $R^5R^6NSO_2$-, $R^5S(O_2)N(R^6)$-, $R^5S(O)$-, $R^5S(O_2)$-, C_1-C_3 alkyl, C_1-C_3 alkoxy, C_1-C_3 alkoxy-C_1-C_3 alkyl, C_1-C_3 haloalkyl and C_1-C_3 haloalkoxy and heteroaryl optionally substituted substituted by from 1 to 3 groups independently selected from halogen, nitro, cyano, $R^5C(O)NR^6$-, $R^5OC(O)$-, C_1-C_3 alkyl, C_1-C_3 alkoxy, C_1-C_3 haloalkyl, C_1-C_3 haloalkoxy and a heterocyclyl group. R^c is selected from 1,1-difluoroethyl, 1-fluoro-1-methylethyl and trifluoromethyl. R^d is selected

		from hydrogen, halogen, cyano, C_1-C_6 alkyl and C1-C6 haloalkyl; R^3 is selected from halogen, hydroxyl, —$NR^{14}R^{15}$ or any of the following groups  R5 and R6 are, independently, selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C4 alkoxy C1-C4 alkyl, C1-C6 cyanoalkyl, or R5 and R6 together with the carbon atoms to which they are attached form a 3-6 membered saturated or partially unsaturated ring optionally comprising from 1 to 3 heteroatoms independently selected from S, O and N and optionally substituted with from 1 to 3 groups independently selected from halogen and C1-C6 alkyl; R7 and R8 are, independently, selected from C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, a C5-C10 monocyclic heteroaryl group comprising from 1 to 4 heteroatoms independently selected from N, O and S and optionally substituted with from 1 to 3 groups independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl and C1-C3 alkoxy and a C6-C10 aryl group optionally substituted with from 1 to 3 groups independently selected from halogen, nitro, cyano, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl and C1-C3 haloalkoxy; R9 is selected from C1-C6 alkyl and benzyl optionally substituted with from 1 to 3 groups independently selected from halogen, nitro, cyano, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl and C1-C3 haloalkoxy; R14 and R15 are, independently, selected from hydrogen, C1-C20 alkyl, C1-C20 haloalkyl, C2-C20 alkenyl, C2-C20 alkynyl, or R14 and R15 together with the carbon atoms to which they are

		attached form a 3-6 membered saturated or partially unsaturated ring optionally comprising from 1 to 3 heteroatoms independently selected from S, O and N and optionally substituted with from 1 to 3 groups independently selected from halogen and C1-C6 alkyl.
738/2015	PFIZER INC. U.S.A.	"A PHARMACEUTICALLY ACCEPTABLE SALT OF -3,4-DIHYDROISOQUINOLIN-1(2H)-ONE COMPOUND" C07D401/06, C07D401/14, C07D 403/14, C07D 471/04, C07D413/06, C07D413/14 & C07D407/14. **143165** The present invention relates to a pharmaceutically acceptable salt of compound of formula (II- A):  (II-A), Wherein; R^1 is C_1-C_4 alkyl or halo; R^2 is 5-6 membered heteroaryl optionally substituted by 1 to 3 R^{32}; R^3 is H; R^4 is H or halo; m is 0 and R^5 is absent; each R^{32} is independently -Cl, -F, -OH, -CH_3, -CH_2CH_3, -CF_3, -CH_2OH, -CH_2OCH_3, -OCH3, -OC_2H_5, -OCF_3, -CN, -C(O)NH_2, -C(O)$NHCH_3$, -C(O)$N(CH_3)_2$, -$NHC(O)CH_3$, -NH_2, - $NHCH_3$, -

		$N(CH_3)_2$, cyclopropyl, 4-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl, where said 4-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl are optionally substituted by 1 to 3 halo, C_1-C_4 alkyl or C_1-C_4 alkoxy, which are independently selected; X and Z are independently C_1-C_4 alkyl; and Y is H. The present invention further provides a pharmaceutical composition comprising above said pharmaceutically acceptable salt of a compound and a pharmaceutically acceptable carrier or excipient which is useful for treatment of abnormal cell growth, including cancer.
16/2018	PLEXXIKON, INC., U.S.A.	"Pharmaceutically acceptable salt of Pyrrolo [2,3-b] pyridine Compond for Modulating C-fms and/or C-kit Activity" C07D471/04 & A61K31/437. **143166** Pharmaceutically acceptable salt of a compound active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith is composition useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions.
334/2018	FB Genetics (Pvt.) Ltd., Pakistan	"Development of Herbicide and Sucking Pest Resistant Plant (Kalgin-5) by the Over-Expression of Constitutive Promoters Driven Tetra Gene Construct" A01N 63/02 & C07K14/435. **143167** The present invention refers to the plurality of polynucleotide sequence (SEQ ID NO. 21) comprising three sucking pest resistant genes including an insecticidal Tma12 gene (SEQ. ID NO. 18) from the fern Tectaria macrodonta , a

		crow dipper gene PTA (SEQ ID NO. 19) and an Allium sativum gene ASAL (SEQ. ID NO. 20) and a Re-PAT gene (SEQ. ID NO. 17) transformed in a plant e.g. mono/dicot plant, that are encoded to provide insecticidal and herbicidal toxin proteins in a transgenic plants having constitutively targeted expression, resulting in the decreased resistance development against insecticidal toxins proteins and increased efficacy against the insect mortality particularly whitefly and jassid. The invention also refers to an assay for detecting the presence of transgenic plant (Kalgin-5) event in its genome and provides methodology to identify Transgene/genome junction based on DNA sequences.

SEALING FEES DUE-

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of **Rs.6750/-** should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

Accepted No.	Applicant Name	Application No.
143070	IMMUNOLIGHT, LLC USA	379/2008
143071	ELI LILLY AND COMPANY USA	766/2011
143072	CRYSTAL LAGOONS (CURACAO) B.V. Curacao	200/2012
143073	Stamicarbon B.V The Netherlands	276/2013
143074	Regeneron Pharmaceuticals, Inc. USA	394/2013
143075	F. HOFFMANN-LA ROCHE AG Switzerland	597/2013
143076	ELI LILLY AND COMPANY USA	828/2013
143077	DOVERFIELD EXPORTS UAE	480/2015
143078	Synthomer Sdn. Bhd. Malaysia	803/2015
143079	Saurer Components GmbH Germany	108/2016
143080	Starlinger & Co Gesellschaft m.b.H., Austria	424/2016
143081	GEMTIER MEDICAL (SHANGHAI) INC., China	721/2016

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

Design No.	Title & Class	Applicant
14/06/2019		
19919	BOTTLE (Class-03)	M/s. Qarshi Brands (SMC) (Pvt.) Ltd.,

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
10-06-2019			
1.	19121	Plastic Bottle (Class-03	Imran Ahmad
2.	19318	Solar Multi-purpose Van (Class-01)	Muhammad Aslam Azad
3.	19464	ELECTRIC MOTORCYCLE (Class-12)	VINFAST TRADING AND PRODUCTION LIMITED LIABILITY COMPANY
4.	19544	JERRY CAN (Class-03)	Shakil Ashaf
13-06-2019			
5.	18979	Packing Carton (Class-5)	Hefei Yili Dairy Co.,Ltd.,
6.	19501	DOOR (Class-01)	Mr,Ghalib Mehmood (prop) . M/S,Polymer Tek,
7.	19502	DOOR (Class-01)	Mr,Ghalib Mehmood (prop) . M/S,Polymer Tek,
8.	19515	DOOR (Class-01)	Mr,Ghalib Mehmood (prop) . M/S,Polymer Tek,
9.	19516	DOOR (Class-01)	Mr,Ghalib Mehmood (prop) . M/S,Polymer Tek,
10.	19517	DOOR (Class-01)	Mr,Ghalib Mehmood (prop) . M/S,Polymer Tek,
11.	19566	Plate (Class-03)	DOVE MELAMINE WARE
12.	19567	Plate (Class-03)	DOVE MELAMINE WARE
13.	19383	RAZOR HANDLE (Class-03)	Wenzhou Mers Razor Works Co., Ltd ,

-sd-

(Dr. Muhammad Fayyaz Ahmad)
Controller of Patents
& Registrar of Designs
Ph: 99230591